Loading peptide directory…
Editorial entries for every peptide we cover — each page links the vendors that carry it, the reviews users have left, and the literature behind it.
5-Amino-1MQ (5-amino-1-methylquinolinium) is not a peptide but is frequently marketed alongside peptides. In the reviewed sources it remains experimental, with no approved human indication and no human clinical efficacy program that could be verified from primary sources.
AOD9604 (Fragment 176-191) is a synthetic analog derived from the C-terminal lipolytic region of human growth hormone, originally explored as an anti-obesity agent. Preclinical work supports adipose-centered lipolysis through β-adrenergic signaling, but human efficacy data have been inconsistent across development programs.
"Insulin" is a drug class, not one marketed compound. There are multiple human insulins and engineered analogs, with formulation-specific kinetics, dosing, and storage rules. The hormone is essential for survival in type 1 diabetes and a core escalation step in type 2 diabetes. Representative regular human insulin labels (Humulin R, Novolin R) anchor the safety and pharmacology summary here.
Mazdutide (IBI362, LY3305677) is a once-weekly synthetic oxyntomodulin analogue with a fatty-acyl moiety for extended exposure. It is a dual GLP-1R / GCGR agonist. Innovent has reported NMPA approval in China for chronic weight management and later for glycemic control in adults with type 2 diabetes; outside China it remains investigational.
MOTS-c is a mitochondrial-derived peptide, not a conventional secretagogue or growth factor. Encoded within mitochondrial 12S rRNA, it has become a major research focus in metabolism, exercise biology, and healthy aging. In animals it behaves like an exercise-responsive metabolic regulator.
Retatrutide (LY3437943) is a once-weekly synthetic peptide and the most-advanced "triple G" agonist in development. A single molecule activates all three of GLP-1R, GIPR, and GCGR. As of 2026 it remains investigational, with peer-reviewed phase 2 obesity data and company-reported phase 3 readouts in type 2 diabetes; no marketed label exists yet.
Tirzepatide is the active ingredient in Mounjaro and Zepbound. It is an FDA-approved synthetic peptide that activates both GIP and GLP-1 receptors. The current Zepbound label covers chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity; Mounjaro is approved for type 2 diabetes. Tirzepatide products were first approved in the U.S. in 2022.